news roundup
IQVIA Biotech is the company's new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions suite is designed to offer simplified operating procedures, specialized teams, and services, including initial planning to trial design and implementation to market launch and commercialization.
| Advertisement
Tell us what you think about clinical operations and receive a $5 Amazon gift card!
 Take the short survey |
Proscia, a digital pathology solutions provider, has released a new edition of the company's flagship digital pathology platform. The Concentriq Commercial Research Edition is an image management solution purpose-built to help pharmaceutical, biotechnology, and commercial research organizations more readily incorporate and centralize pathology data into research, discovery, and clinical trials.
Sharp has invested into its Clinical IRT System and added the following enhancments: a supply forecaster to predict patient enrollment and clinical supply consumption; warehouse return system to perform accountability for returns from clinical sites, and dynamic randomization with minimization and simulation to help determine impact on the treatment type and allow sufficient clinical supplies to be allocated to the clinical study.
Zagreb, Croatia-based CRO Optimapharm has acquired Switzerland-based Denothex, bringing its offices to over 14 countries in Euorpe. Denothex focuses on biotech and medical device services in oncology.
Articles
This peer-reviewed article looks at a new approach to site selection for clinical trial planners, whereby a portfolio of sites is selected based on advanced analytical models, with the goal of maximizing the overall value of a portfolio of sites, and to align it with clinical trial goals and limited resources.
Blog Posts
In a policy speech, FDA Commissioner Scott Gottlieb, pointed to "seamless integration" of digital technology in clinical trials will help "bring clinical trials to the patient." This involves moving prospective data collection "outside the brick and mortar boundaries of traditional clinical research facilities," instead of always requiring patients to travel to investigator sites.
|
